Back to top
more

Second Sight Medical Products, Inc. (EYES)

(Delayed Data from NSDQ)

$0.99 USD

0.99
81,859

+0.01 (0.58%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Company News for May 13, 2021

by Zacks Equity Research

Companies in the news are: TM, LHDX, EYES, CVI

Second Sight Medical Products (EYES) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Second Sight Medical Products (EYES) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Second Sight Medical Products (EYES) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Company News for Apr 1, 2020

by Zacks Equity Research

Companies In The News Are: KNSA, EYEG, VBIV, EYES

Second Sight Medical Products (EYES) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 4.08% and -40.12%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Second Sight Medical Products (EYES) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Second Sight Medical Products (EYES) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 0.00% and -49.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Second Sight Medical Products (EYES) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Second Sight Medical Products (EYES) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Second Sight Medical Products (EYES) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 0.00% and 183.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Second Sight Medical Products (EYES) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Second Sight Medical Products (EYES) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Second Sight Medical Products (EYES) delivered earnings and revenue surprises of -66.67% and -33.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Second Sight Medical Products (EYES) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks.com featured highlights include: VALE, Second Sight, Carbonite, Arconic and vTv

by Zacks Equity Research

Zacks.com featured highlights include: VALE, Second Sight, Carbonite, Arconic and vTv

Sanghamitra Saha headshot

Get Over Bargain Hunting: Tap 5 Stocks With Rising P/E

by Sanghamitra Saha

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight

by Zacks Equity Research

Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight

Sanghamitra Saha headshot

Rising P/E an Overlooked Criterion: 5 Top Stocks

by Sanghamitra Saha

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratio.

Second Sight Medical Products Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Second Sight Medical Products has been struggling lately, but the selling pressure may be coming to an end soon

Second Sight Medical Products (EYES) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Second Sight Medical Products (EYES) delivered earnings and revenue surprises of 21.43% and -9.44%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Second Sight Medical Products (EYES) Q3 Earnings Expected to Decline

by Zacks Equity Research

Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Second Sight Medical Products (EYES) Q3 Earnings Preview: How Are Events Shaping Up?

by Zacks Equity Research

Second Sight Medical Products (EYES) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Second Sight Medical Products (EYES): Moving Average Crossover Alert

by Zacks Equity Research

Second Sight Medical Products, Inc. (EYES) could be a stock to avoid from a technical perspective

    Second Sight (EYES) Catches Eye: Stock Jumps 12.7%

    by Zacks Equity Research

    Second Sight (EYES) saw a big move last session, as its shares jumped nearly 13% on the day, amid huge volumes.

      Second Sight Medical (EYES) in Focus: Stock Moves 12.1% Higher

      by Zacks Equity Research

      Second Sight Medical (EYES) was a big mover last session, as the company saw its shares more than 12% on the day amid huge volumes.